Find latest Non-Small Cell Lung Cancer videos
·
500+ videos
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Targeted Therapy for NTRK Fusion-Positive Cancers
By
Springer Healthcare IME
FEATURING
Alex Drilon
By
Springer Healthcare IME
FEATURING
Alex Drilon
86 views
October 1, 2024
In this video, Alexander Drilon summarises the targeted therapy options for NTRK fusion-positive non-small cell lung cancer (NSCLC).
View our CME-accredited clinical pathway tool, designed to guide you through the best practices for detection and treatment of NTRK fusions in NSCLC at https://nsclc-biomarkers-ime.springermedicine.com/courses/detecting-and-targeting-ntrk-fusions-in-nsclc/
This tool is summarised into a free, downloadable practice aid available for use directly in your clinical practice. Complete the short evaluation form available on the page to collect your CME credits.
This independent medical education program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
View our CME-accredited clinical pathway tool, designed to guide you through the best practices for detection and treatment of NTRK fusions in NSCLC at https://nsclc-biomarkers-ime.springermedicine.com/courses/detecting-and-targeting-ntrk-fusions-in-nsclc/
This tool is summarised into a free, downloadable practice aid available for use directly in your clinical practice. Complete the short evaluation form available on the page to collect your CME credits.
This independent medical education program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Comments 0
Login to view comments.
Click here to Login